Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 2
1987 1
1990 1
1993 1
1994 1
1995 1
1997 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Topical tiacrilast, a potent mast cell degranulation inhibitor, does not improve adult atopic eczema.
Czarnetzki BM, Brechtel B, Braun-Falco O, Christophers E, Schöpf E, Reckers-Czaschka R, Baudin M, Dupuy P. Czarnetzki BM, et al. Dermatology. 1993;187(2):112-4. doi: 10.1159/000247218. Dermatology. 1993. PMID: 8102913 Clinical Trial.
Tiacrilast is a potent mast cell degranulation inhibitor in vitro and in animal studies. Since mast cells and their mediators are possibly involved in atopic eczema, we have studied a topically applied 3% hydrogel formulation of tiacrilast against vehicle in a multi …
Tiacrilast is a potent mast cell degranulation inhibitor in vitro and in animal studies. Since mast cells and their mediators are pos …
The pharmacological profile and initial clinical evaluation of tiacrilast (Ro 22-3747): a new antiallergic agent.
Welton AF, Dunton AW, McGhee B. Welton AF, et al. Agents Actions. 1986 Jun;18(3-4):313-7. doi: 10.1007/BF01964990. Agents Actions. 1986. PMID: 2428219 Clinical Trial.
Tiacrilast (Ro 22-3747) is an allergic mediator release inhibitor which has demonstrated potent oral activity in two IgE-mediated animal models of immediate hypersensitivity: the rat passive cutaneous anaphylaxis test (ID50 of 0.65 mg/kg) and a model in which anaphylactic …
Tiacrilast (Ro 22-3747) is an allergic mediator release inhibitor which has demonstrated potent oral activity in two IgE-mediated ani …
Mast cell involvement in murine hair growth.
Paus R, Maurer M, Slominski A, Czarnetzki BM. Paus R, et al. Dev Biol. 1994 May;163(1):230-40. doi: 10.1006/dbio.1994.1139. Dev Biol. 1994. PMID: 8174779
In vivo, the IgE-independent MC secretagogues, compound 48/80 and ACTH, induced anagen in mouse telogen follicles after intracutaneous administration, while inhibitors of mast cell degranulation (cromoglycate, tiacrilast) and antagonists of selected MC products (clemastin, …
In vivo, the IgE-independent MC secretagogues, compound 48/80 and ACTH, induced anagen in mouse telogen follicles after intracutaneous admin …
Effect of tiacrilast, a mast cell mediator-release inhibitor, on murine experimental contact dermatitis.
Csatò M, Judák R, Bozóky B, Czarnetzki BM. Csatò M, et al. Skin Pharmacol. 1990;3(3):164-70. doi: 10.1159/000210866. Skin Pharmacol. 1990. PMID: 1981832
The effect of tiacrilast, a mast cell mediator-release inhibitor, was studied in dinitrofluorobenzene-induced allergic and croton oil- or dimethyl sulfoxide-induced irritant murine contact dermatitis. ...
The effect of tiacrilast, a mast cell mediator-release inhibitor, was studied in dinitrofluorobenzene-induced allergic and croton oil …
Pharmacokinetics of single and multiple ascending doses of the antiallergic agent tiacrilast in man.
Massarella JW, Silvestri TM, Keigher N, Pao J, Dunton A. Massarella JW, et al. Int J Clin Pharmacol Res. 1987;7(2):121-7. Int J Clin Pharmacol Res. 1987. PMID: 3583494
Five groups of six healthy subjects received single oral doses of 150, 300, 450, 600 or 750 mg tiacrilast 150 mg capsules, followed 24 h later by the same dose given every 6 h for 7 days, in a study designed to assess the pharmacokinetics of single and multiple doses of …
Five groups of six healthy subjects received single oral doses of 150, 300, 450, 600 or 750 mg tiacrilast 150 mg capsules, followed 2 …
Inhibitor of the release of mast cell mediators does not improve the psoriatic plaque.
van de Kerkhof PC, Goos M, Christophers E, Baudin M, Dupuy P. van de Kerkhof PC, et al. Skin Pharmacol. 1995;8(1-2):25-9. doi: 10.1159/000211327. Skin Pharmacol. 1995. PMID: 7786522 Clinical Trial.
Therefore, the aim of the present investigation was to find out whether a 4-week treatment period with Tiacrilast, a highly potent inhibitor of mast cell degranulation, might have antipsoriatic potential. ...No statistically significant improvement of the Tiacrilast …
Therefore, the aim of the present investigation was to find out whether a 4-week treatment period with Tiacrilast, a highly potent in …